DEVELOPMENT AND EVALUATION OF GRANISETRON TRANSDERMAL PATCHES FOR SUPPORTIVE THERAPY OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Abstract

The study was designed to fabricate transdermal patches of Granisetron hydrochloride for curbing the chemotherapy induced nausea and vomiting and also evaluated the physicochemical properties and performance of transdermal patches of Granisetron hydrochloride. The formulations were assessed for thickness, folding endurance, content uniformity, weight, surface pH, percentage flatness, percentage elongation, moisture content, moisture uptake, and swelling index. Thickness ranged from 0.231 ± 0.004 mm to 0.393 ± 0.011 mm, affecting drug-loading capacity and flexibility. Folding endurance varied significantly, with TPF4 showing the highest flexibility and durability. All formulations demonstrated high content uniformity, ensuring consistent drug delivery. The surface pH values were close to the skin's natural pH, indicating good tolerance. High flatness values suggested that the patches maintained their shape well. TPF6 exhibited the highest elongation, providing superior flexibility. Moisture content and uptake influenced stability and drug release, with TPF4 showing the highest values. Swelling studies revealed varying fluid absorption rates, impacting drug release and patch performance. Overall, TPF4 and TPF6 were identified as promising formulations, balancing drug delivery efficacy, flexibility, and stability. Further in vivo studies are recommended to confirm these findings and optimize the formulations for clinical use.